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Abstract
Background Quality of life (QoL) measures are important
in growth hormone (GH) deﬁciency (GHD) in adults.
Ideally, for use in health economics, QoL should be
expressed in utilities. The aim of this study was to obtain
reference values and utilities for QoL of GHD in adults in
Belgium and the Netherlands.
Methods The study was conducted in three stages: (1)
The Quality of Life-Assessment for Growth Hormone
Deﬁciency in Adults (QoL-AGHDA) and the EQ-5D were
administered in a representative sample of 6,875 individuals
from the Belgian and 1,400 individuals from the general
Dutch population. The EQ-5Dindex c a nb eu s e dt oe s t i m a t e
utilities. Using a regression, utilities were predicted from the
QoL-AGHDA. (2) QoL-AGHDA scores were obtained from
299 Belgian and 234 Dutch adult patients with GHD and no
GH replacement. These scores were converted to utilities
and compared the burden of disease with other patient
groups. (3) To test the criterion validity, the ‘standard’
EQ-5Dindex was used in a subsample of 64 Dutch GHD
patients and compared with the predicted utilities.
Results We obtained data from 1,026 Belgian (response
rate = 15%) and 1,038 Dutch respondents (response
rate = 74%). The Belgian mean QoL-AGHDA value was
6.95 (90% range = 14.00), and the Dutch mean was 5.48
(range = 13.00). The R
2 of the regression model to predict
the EQ-5Dindex was 0.360 (Belgium) and 0.482 (the
Netherlands). We demonstrated a considerable burden of
disease in GHD patients, comparable to patients with
hypertension or with type II diabetes. The criterion validity
was 0.407 (intraclass correlation, ICC).
Conclusions Interventions in GHD can now be evaluated
more validly in Belgium and the Netherlands.
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Background
The availability of general population values for Quality of
Life (QoL) measures is important for clinical assessment of
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DOI 10.1007/s10198-010-0241-7patients and may facilitate health economic evaluations.
Ideally, for use in health economics QoL should be
expressed in ‘utilities’, but utilities can often not be pro-
duced by applying conventional clinical QoL measures.
The Quality of Life-Assessment for Growth Hormone
Deﬁciency in Adults (QoL-AGHDA) is one of the most
used conventional clinical QoL measures in adult growth
hormone deﬁciency (GHD). The aim of this study was to
obtain general population values for the QoL-AGHDA, to
develop a model to obtain utility values from the QoL-
AGHDA and to further explore the burden of disease of
GHD in adults in Belgium and the Netherlands.
Adults with longstanding, untreated GHD have multiple
somatic impairments, including altered blood biochemis-
try, metabolism, body composition, and muscular and
aerobic performance. They experience functional limita-
tions, diminished productivity, social isolation, excessive
fatigue and poorer QoL [1]. Given the impact of GHD on
QoL, the assessment of QoL is crucial in the appraisal of
the medical need and the effects of interventions. The aim
of this study was to enhance the assessment of QoL in
GHD in three ways: (1) First, we collected Belgian and
Dutch reference values for the QoL-AGHDA based on
samples from both the general population and patient
samples. The QoL-AGHDA is not legitimate for health
economic evaluation; therefore, it is necessary to make
relevant adaptations. To support health policy evaluations
of intervention in GHD, we made the QoL-AGHDA suit-
able for health economic evaluations in the Netherlands
and Belgium. (2) Second, we compared the burden of
disease of patients with GHD with other patient groups. (3)
We tested the validity of the QoL-AGHDA outcomes for
use in economic evaluations. Because the health economic
aspects of this study are less known than the collection of
reference values in patients and the general population, we
have describe these aspects in more detail below.
Adapting the QoL-AGHDA for QALY analysis
Health economic evaluations are becoming increasingly
important in health policy-making in the Netherlands and
Belgium [2–4]. For a valid health economic evaluation of
GH substitution, convincing estimates of QoL are crucial
but undeveloped [5, 6]. In health economics QoL outcomes
are preferably measured in quality-adjusted life years
(QALYs). QALYs are estimated by multiplying the num-
ber of life years with a quality of life value of ‘utility’ that
has the value 1.00 for ‘perfect health’ and 0.00 for ‘a health
state comparable to the value of death’. For instance, if the
utility for sitting in a wheelchair has a value of 0.6, than 2
life years in a wheelchair stands for 1.2 QALY. QALYs are
particular useful to provide a common metric of burden of
disease across the entire spectrum of diseases. For instance,
with QALYs it becomes possible to compare the additional
effects of a wheelchair on QoL with a life-saving opera-
tion. The most complex aspect of QALYs is the estimation
of the utility. Fortunately, there are special QoL question-
naires like the EQ-5D that can provide this utility on a
routine basis [7]. Most questionnaires like the EQ-5D are
generic questionnaires; they can be used in a wide variety
of diseases. A drawback of this generic feature is that these
one-size-ﬁts-all questionnaires might miss disease-speciﬁc
symptoms that are relevant for QoL of these patients. A
recent development is to validate disease-speciﬁc ques-
tionnaires in such a way that these questionnaires can also
provide a utility that can be used in QALY analyses [8].
Such validations can be useful when the generic QoL
questionnaires are found to be insufﬁciently sensitive to
pick up relevant changes in QoL or when generic instru-
ments have not been included in an investigation. Both
motivations apply in GHD research [6]. For this reason,
researchers in the UK and Sweden have linked the QoL-
AGHDA and the EQ-5D in a way that QoL-AGHDA data
collected in GHD patients can be used in QALY-type
calculations [9, 10]. To achieve this, in both the UK and
Sweden, investigators used a regression of the EQ-5Dindex
on the QoL-AGHDA scores in samples of the general
population. After such regression in the general population,
the investigators could estimate the EQ-5D indexes from
patient QoL-AGHDA scores. This method assumes that the
relationship between the QoL-AGHDA and the EQ-5D in
the general population is a valid predictor of the same
relationship in patients. This crucial assumption can be
tested if the EQ-5D and the QoL-AGHDA are both
administered in a subsample of patients. Testing this
assumption forms part of this paper.
Comparing the burden of GHD with other diseases
Because the scores on the QoL-AGHDA only relate to
disease-speciﬁc factors, it is difﬁcult to relate the QoL-
AGHDA scores to burden of disease in other patient
groups. When the burden of GHD is measured using the
EQ-5D or when the score of the QoL-AGHDA is trans-
formed into an EQ-5Dindex, such comparison becomes
possible. The possibility of describing the burden of GHD
relative to other diseases is important, as ‘burden’ is
recognised as an important factor in reimbursement deci-
sions [11]. In the Netherlands, for example, this recognition
has recently resulted in a formal recommendation to
incorporate burden of disease in reimbursement decisions
[12]. In this article we estimated the burden of GHD in
generic terms and compared it with burden in other
diseases.
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123Materials and methods
Questionnaires
QoL-AGHDA
One of the most frequently used QoL assessment instru-
ments in adult GHD is the QoL-AGHDA. The QoL-
AGHDA is a disease-speciﬁc instrument based on the
concept that ‘‘QoL is the degree to which human needs
are satisﬁed’’ [13]. The QoL-AGHDA was developed
following in-depth interviews in adult patients with GHD
and consists of 25 items with yes/no answers, acknowl-
edging or denying GHD-related problems [14]. Examples
of questionings are: ‘‘I feel a strong need to sleep during
the day’’ and ‘‘I often feel lonely even when I am with
other people’’. All items are listed in Table 2.T h em o s t
used scoring mode is an overall sum score, without any
references to a possible dimensional structure. In line
with that approach, Rasch models are often employed,
and much attention is given to the unidimensionality of
the sum score, which represents the ‘need’-driven per-
spective on QoL [15] .Ah i g hQ o L - A G H D As c o r e
denotes that ‘less needs are satisﬁed’, and thus a lower
QoL, with a score of 25 as maximum. The high number of
items, all loading on an unidimensional score, contributes
to a high reliability (test-retest, Spearman rank C 0.86)
and a high level of internal consistency (Cronbach’s
a C 0.88) [14]. Mean values in the normal population
range between 4 an 7 in various international studies [16].
A score of 11 or more on the QoL-AGHDA is one of the
UK National Institute for Health and Clinical Excel-
lence’s (NICE) requirements for GH replacement therapy
[17]. The total sum score decreases when patient receive
GH replacement therapy and approaches the mean value
of the normal population [16].
The QoL-AGHDA is a typical disease-speciﬁc instru-
ment, as it only targets one group of patients. This is one of
the features that distinguish it from generic instruments like
the EQ-5D. Because the QoL-AGHDA is tailored for
GHD-related QoL, one can safely assume that its sensi-
tivity is higher than a generic instrument. A downside of
the speciﬁcity is that scores of the QoL-AGHDA are dif-
ﬁcult to compare with scores form other QoL instruments.
Moreover, unlike the EuroQol, the QoL-AGHDA does not
provide a utility score necessary for health economic
analysis. If one can transform QoL-AGHDA scores into
EuroQol scores, then outcomes of the QoL-AGHDA would
be comparable with other (generic) QoL instruments, and
utility for the use in health economic analyses would be
available. In the present research effort, we want to
establish just that.
EQ-5D
The EuroQol EQ-5D is a ﬁve-item generic QoL question-
naire specially designed for health economic evaluations
that involves QoL estimates. The ﬁve items cover the ﬁve
dimensions of QoL: mobility, self care, usual activities,
pain/discomfort and anxiety/depression. The answers on
the ﬁve items are summarized into an index on which 1.00
represents ‘full health’ and 0.00 the value of ‘being dead’
[7]. The transformation of the ﬁve items into an index was
done based on formal national standards. In Belgium this
standard is based on a ‘visual analogue scale’ valuation
study, whereas the Dutch standard is based on a ‘time
trade-off’ [18, 19].
Patient samples
The study involves three separate samples:
(1) The ﬁrst cohort was elicited from the general
population of Belgium and the Netherlands. These
subjects ﬁlled in both the QoL-AGHDA and EQ-5D.
The QoL-AGHDA data from these two samples were
used for deriving national population reference val-
ues. The regression of the EQ-5D on the QoL-
AGHDA was used to transform QoL-AGHDA scores
into utilities that could be used in health economic
analyses.
(2) The second cohort comprised Belgian and Dutch
patients with GHD who contributed QoL data to
KIMS (Pﬁzer International Metabolic Database) [20].
These patients ﬁlled in only the QoL-AGHDA prior
to growth hormone treatment, providing scores for the
Belgian and Dutch patient populations.
(3) The last cohort was a subsample of 64 Dutch patients
with GHD who ﬁlled in both the QoL-AGHDA and
EQ-5D. This sample was used to test the criterion
validity of the regression analysis of the EQ-5Dindex
score on the QoL-AGHDA made in the Dutch general
population.
Population reference QoL-AGHDA and QALY values
Members of the Belgian population were sampled in Jan-
uary 2007 by InSites Consulting, a professional institute for
public opinion and marketing research. Out of the total
panel of *500,000 individuals, 6,875 individuals aged
over 18 years were selected and invited to take part in the
online survey. The invited sample was representative of the
national distribution of age, sex and language (region).
These socioeconomic variables are the usual variables to
test whether a sample is representative of the population.
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sample should be representative of the distribution of the
variable of interest, in this case ‘health’. We therefore
asked the respondents to ﬁll in the ‘general health ques-
tion’, a question with a ﬁve-level Likert scale, which is
often asked as part of national statistical monitors. In
Belgium this monitor was undertaken by the Belgian
National Institute of Statistics (http://www.statbel.fgov.be).
In this way we could check whether our sample was rep-
resentative of ‘general health’.
Members of the Dutch population were sampled by TNS
NIPO, a professional Dutch institute for public opinion and
marketing research. This research institute has a panel of
over 200,000 individuals who are interviewed regularly via
the Internet. In July 2005, a sample of 1,400 individuals
aged over 18 years was drawn from this panel. The sample
was made representative of the national distribution of age,
sex, region, urbanisation and social class. Like in the
Belgium sample, we asked the general health question to
check whether the sample was representative for general
health. The distribution of the outcome of the general
health question was compared to the ﬁgures of the Central
Bureau of Statistics (www.cbs.nl).
The QoL-AGHDA in GHD patients
Patient data from Belgium and the Netherlands were
retrieved from the KIMS database. The KIMS database is
part of an international pharmaco-epidemiological survey,
launched in 1994 at the request of endocrinologists and
health-care decision-makers to monitor the outcomes and
safety of long-term GH replacement therapy (Genotro-
pin) in adults with GHD being treated in a conventional
clinical setting. The study to date contains data on more
than 14,000 patients from 31 countries. The other aims of
KIMS are to improve understanding of the consequence of
GHD in adult hypopituitarism and to contribute to opti-
misation of GH replacement [20].
The Belgian patient sample consisted of 370 participants
[mean (SD) age at entry into KIMS: 43 (15.1) years] and
the Dutch sample comprised 286 participants [44 (15.5)
years]. The majority of patients in both countries acquired
pituitary insufﬁciency and consequent GHD during adult-
hood (77 and 76% in Belgium and the Netherlands,
respectively). The severity of hypopituitarism, expressed as
a number of pituitary hormone deﬁcits, varied from iso-
lated GHD to panhypopituitarism (18% of patients). The
proportion of the number of deﬁcits was similar in both
countries except for isolated GHD. Isolated GHD was less
common in Belgian patients (8%) than in Dutch patients
(13%). The proﬁle of co-morbidities did not differ between
countries with 13–16% of patients reporting hypertension.
In both groups half of the patients developed
hypopituitarism due to the long-term consequences of
surgery for pituitary adenoma with non-functioning pitui-
tary adenoma being most frequent (*30%). QoL was
assessed by the QoL-AGHDA at the entry into the KIMS in
all patients and before GH replacement therapy was started.
Patient subsample to test validity of regression model
A subsample of 64 Dutch GHD patients ﬁlled in both the
EQ-5D and the QoL-AGHDA. Because these patients ﬁlled
in both questionnaires, we could test whether the predicted
EQ-5Dindex (on the basis of the regression of the EQ-5D on
the QoL-AGHDA in the general population) was indeed
comparable with the ‘standard’ EQ-5Dindex (completed
directly by the patients). The mean age of the Dutch patients
who ﬁlled in both the EQ-5D and the QoL-AGHDA was
42.6 (SD = 14.6), and 39% of the patients were female.
Analyses
Scores elicited from disease-speciﬁc questionnaires such as
the QoL-AGHDA in the general population are most likely
to be skewed, because the questionnaire focuses on a
speciﬁc pathology. The use of mean and standard deviation
to determine ‘deviations from normal’ is therefore limited.
For this reason we also present the 90 and 95% cutoff
points of the normal population, which could serve as
clinical benchmarks. The reference values of the general
population samples were weighted for ‘general health’ to
adjust for differences between the samples and general
population health.
We used a multiple regression model to estimate the
EQ-5Dindex from the individual 25 QoL-AGHDA items in
the Belgian and Dutch general population data. All yes/no
answers on the QoL-AGHDA were added as dummies. In
addition to these 25 items, sex and age were added to the
model. In this investigation we were not aiming to explain
the relationship between the QoL-AGHDA and EQ-5D, but
only trying to achieve the best prediction possible. For this
reason the most parsimonious model was not an issue here
[21]. Thus, the model included all 25 items of the QoL-
AGHDA, irrespective of whether the univariate contribu-
tion was statistically signiﬁcant. We did two sensitivity
analyses. To illustrate what would happen if we had tried to
achieve the most parsimonious model, we removed all non-
signiﬁcant contributions from the Dutch model in a
‘backwards elimination analysis’. In addition, we made a
simple regression of the EQ-5Dindex on the QoL-AGHDA
total sum score.
Criterion validity between the estimated EQ-5Dindex
from the QoL-AGHDA and the ‘standard’ EQ-5Dindex was
tested by administering both questionnaires in a subsample
of patients in the Netherlands. The relationship between the
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described by a single-measure intraclass correlation coef-
ﬁcient (ICC) using a two-way ﬁxed effect model (the two
questionnaires are the ﬁxed sample) with ‘absolute agree-
ment’ (SPSS, version 15). We also tested the difference in
mean values with a paired t-test.
Results
Population reference values QoL-AGHDA
and QALY values
Complete QoL-AGHDA data were obtained for 1,026 of
the interviewees (response rate = 15%) of the Belgian
population and 1,038 (response rate = 74%) individuals of
the Dutch general population. The Belgian sample consisted
of 40% French speaking responders and 60% Flemish,
which represents the real distribution in Belgium. The
gender and age distributions were almost equal to data from
the national institutes of statistics of Belgium (http://www.
statbel.fgov.be) and the Netherlands (www.cbs.nl). The
only exception was an underrepresentation of the middle
age groups (40–60 years) in the Dutch sample, with 38%
belonging to that age group although it represents 46% of
the general population in the Netherlands. As the reference
values are presented in age categories, this underrepresen-
tation did not jeopardize the representation per age group.
A different issue was overall health: Overall health is by
deﬁnition related to health-related QoL, but there is, unlike
age,norationaletopresentreferencevaluesfor‘subgroupsof
general health’. In Table 1 it can be seen that some of the
Belgian age groups were healthier, while other subgroup
responders were less healthy compared to the ﬁgures of the
National Institute of Statistics. Overall, the Dutch sample
appears a bit healthier than the general population (Table 1).
The reference values of the general population samples were
therefore weighted by the reported ‘general health’.
The regression of the EQ-5D time trade-off index score
on the 25 items of the QoL-AGHDA is presented in
Table 2. The R
2 in the Dutch general population sample
was 0.482 and 0.360 in the Belgian sample.
In the ﬁrst sensitivity analysis, the ‘backwards elimi-
nation analysis’, 13 of the 25 variables of the QoL-
AGHDA were deleted from the model, and the R
2 dropped
slightly from 0.482 to 0.477. The simple regression of the
EQ-5Dindex on the QoL-AGHDA total sum score produced
a much lower R
2 of 0.356.
The QoL-AGHDA in GHD patients
Table 3 presents the patient data. Men report fewer prob-
lems than women (p\0.001), which is often the case in
QoL data [22]. Patients in Belgium seemed to report more
problems than in the Netherlands, but this difference was
not statistically signiﬁcant (p = 0.073). The differences
between the countries in the EQ-5Dindex derived from the
QoL-AGHDA must be interpreted with caution, as the
difference can be attributed to both difference in ‘true
patient score’ and also to other differences like the valua-
tion function in Table 2 (see also the ‘‘Discussion’’ sec-
tion). In Fig. 1, the estimated patient EQ-5D score is
compared with the EQ-5Dindex of asthma [23], hyperten-
sion [23], type II diabetes [24], low back pain [23], Par-
kinson’s disease [25] and intermittent claudication [26].
The results suggest that the burden of GHD (mean value
0.7635) is between the burden of asthma (0.79) and dia-
betes (0.69), and well below the average of the general
Dutch population in this study (0.88).
Patient subsample to test the validity of the regression
model
The correlation between the estimated EQ-5Dindex on the
basis of the QoL-AGHDA and the ‘standard’ EQ-5Dindex
was 0.407 (intraclass correlation). The difference between
the estimated mean EQ-5Dindex on the basis of the QoL-
AGHDA (0.7387) and the mean of ‘standard’ EQ-5Dindex
(on the basis of the ‘standard’ EQ-5D in patients: 0.7027)
did not reach a statistically signiﬁcant difference
(t = 1.132, p = 0.262).
Discussion
We provided Dutch and Belgian reference values for the
QoL-AGHDA and adapted the QoL-AGHDA for use in
health economic evaluations. We demonstrated the crite-
rion validity of the health economic valuation method, and
we showed that the burden of GHD is considerable.
Theoretical reﬂection
It is tempting to try to interpret the slightly lower QoL
values of the patients in Belgium compared to the Dutch. It
is, however, difﬁcult to understand these differences,
because there are several possible explanations. For
instance, patients in Belgium may be more inclined to
express their QoL limitations. Also a subtle difference in
the French and Dutch translations of the questionnaire may
cause differences. Another reason might be the structural
difference between the estimated scores for the two EQ-5D
indices in Belgium and the Netherlands, i.e., between
values derived using the visual analogue scale technique in
Belgium and those in the Netherlands derived using the
time trade-off technique [27]. Moreover, subtle differences
QoL-AGHDA reference values and utility 247
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also contribute to the difference. Most of these explana-
tions provide additional arguments concerning the routine
use of national reference values emanating from other
countries. The national reference values presented here are
in line with that reasoning.
We performed two sensitivity analyses: To illustrate
what would happen if we had tried to achieve the most
parsimonious model, we removed all non-signiﬁcant con-
tributions from the Dutch model in a ‘backwards elimina-
tion analysis’. In this, the R
2 dropped only slightly from
0.482 to 0.477. An alternative to the regression of the
individual item scores of the EQ-5Dindex on the individual
QoL-AGHDA items is a regression of the EQ-5Dindex on
the QoL-AGHDA sum score. Unlike the distinction
between a full model and the parsimonious model, this
variant makes a large difference: the R
2 of the regression of
the QoL-AGHDA sum score on the EQ-5D score is only
0.356 compared to 0.482 for the individual items.
Kołtowska-Ha ¨ggstro ¨m et al. constructed a model to esti-
mate the EQ-5Dindex score using the QoL-AGHDA sum
score, the square of the QoL-AGHDA sum score and
several SES variables and interactions [9]. The R
2 of this
‘‘full model’’ was not much higher than our parsimonious
model based on the QoL-AGHDA sum score, age and sex
(0.38 versus 0.36). In a successive article, Kołtowska-
Ha ¨ggstro ¨m et al. abandoned this approach, and the new
model consisted of the variable age; sex and all 25 indi-
vidual items of the QoL-AGHDA which all were entered as
dummies, as in the present investigation [10]. This model
had a R
2 of 0.42, in between the 0.36 of our Belgium data
and the 0.48 of our Dutch data. Thus, the results of
Kołtowska-Ha ¨ggstro ¨m are in line with the results found
here, and this suggests that, at least in the relationship
between the QoL-AGHDA and the EQ-5Dindex, a saturated
model based on the most important SES variables (age and
Table 1 Mean values of the QoL-AGHDA for the Belgian and Dutch population
N Mean (SD)
QoL-AGHDA
Score
worse 90%
Score
worse 95%
Score
worse 90%
Score
worse 95%
Sample National Bureau
of Statistics (2005)
Non-
weighted
Weighted Non-
weighted
Non-
weighted
Weighted Weighted Report ‘‘less
than good health’’ (%)
Report ‘‘less than
good health’’ (%)
Belgian population
Overall 1,026 6.79 (5.47) 6.95 (5.44) 14.00 17.65 14.00 17.00 19.4 23.1
Male 528 6.02 (5.30) 6.43 (5.33) 13.00 15.50 14.00 16.00 17.2 21.2
18–24 57 7.71 (4.71) 7.73 (4.69) 14.00 16.10 14.00 16.07 5.9 7.2
25–44 195 6.07 (5.66) 5.93 (5.55) 14.00 16.40 13.00 15.92 15.3 12.8
45–64 167 6.15 (5.18) 6.35 (5.29) 14.00 16.00 14.00 16.00 21.5 24.9
65 and older 109 5.69 (5.00) 6.77 (5.22) 13.00 14.00 14.00 15.00 20.7 42.1
Female 498 7.42 (5.59) 7.49 (5.51) 16.00 19.00 15.47 18.04 21.7 24.8
18–24 82 8.71 (5.63) 8.28 (5.52) 16.40 20.00 14.24 20.00 15.5 8.4
25–44 178 7.06 (5.53) 6.70 (5.37) 15.10 18.00 15.00 17.33 21.8 15.0
45–64 160 7.75 (5.76) 7.94 (5.80) 17.00 19.00 17.00 19.21 25.6 29.1
65 and older 78 6.20 (5.06) 7.62 (5.07) 12.10 19.00 13.83 19.00 20.3 49.3
Dutch population
Overall 1,075 4.94 (5.15) 5.48 (5.48) 13.00 16.00 14.00 17.00 16.7 20.1
Male 527 4.51 (4.97) 5.14 (5.40) 12.00 15.00 13.00 17.00 13.7 17.9
18–24
a 46 3.13 (3.64) 3.13 (3.64) 8.30 12.65 8.30 12.65 0.0 9.1
25–44 203 4.48 (5.07) 4.72 (5.31) 12.00 16.00 13.00 16.00 10.8 13.0
45–64 181 4.92 (5.57) 6.00 (6.22) 14.00 17.00 16.00 18.00 16.6 28.1
65 and older 97 4.48 (3.92) 5.35 (4.23) 9.20 12.00 11.00 14.00 20.6 36.0
Female 548 5.36 (5.29) 5.82 (5.54) 13.00 16.00 14.00 17.00 19.5 22.2
18–24 44 6.27 (6.17) 5.93 (5.87) 14.50 22.25 13.94 21.34 15.9 12.8
25–44 214 5.25 (4.94) 5.28 (4.96) 13.00 15.00 13.00 15.00 15.4 15.8
45–64 195 5.18 (5.23) 5.65 (5.45) 13.00 16.00 14.00 16.86 24.1 30.1
65 and older 95 5.53 (5.76) 7.33 (6.56) 14.00 19.20 19.00 21.81 21.1 48.6
Weighting based on the responses to the ‘general health question’ and the statistics of the Belgian National Bureau of Statistics (data from 2005)
and Dutch National Bureau of Statistics (data from 2005)
a In the age category male, age 15 to 24, weighting does not change scores, as there are no responders with less than perfect health
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123sex) and all items of the disease-speciﬁc instrument seems
to be the most favourable model.
A number of items have positive signs, which is
remarkable as all items are conceptually negatively related
to QoL: an additional problem should result in a lower
QoL, and thus a lower EQ-5D index. The most likely
explanation is that the positive signs are reﬂections of
interactions between the variables. Given the high number
Table 2 The regression of the EQ-5D time trade-off index score on the QoL-AGHDA
Variables The Netherlands Belgium
Constant 0.94587 0.93756
Men = 1; woman = 2 -0.00632 -0.01563
Younger than or equal to 25 = 1, otherwise 0 0.02394 0.10171
Older than 25 and younger than or equal to 50 = 1, otherwise 0 0.02968 0.02504
Q01 I have to struggle to ﬁnish jobs -0.01966 -0.01086
Q02 I feel a strong need to sleep during the day -0.00692 -0.01390
Q03 I often feel lonely even when I am with other people -0.00645 -0.03131
Q04 I have to read things several times before they sink in -0.00449 0.00052
Q05 It is difﬁcult for me to make friends -0.00949 0.02414
Q06 It takes a lot of effort for me to do simple tasks -0.16876 -0.09427
Q07 I have difﬁculty controlling my emotions -0.02626 -0.01413
Q08 I often lose track of what I want to say -0.02450 0.00000
Q09 I lack conﬁdence 0.02437 -0.00299
Q10 I have to push myself to do things 0.00552 -0.01325
Q11 I often feel very tense -0.03686 -0.04496
Q12 I feel as if I let people down -0.03184 -0.01642
Q13 I ﬁnd it hard to mix with people -0.00804 -0.01081
Q14 I feel worn out even when I’ve not done anything -0.04822 -0.06042
Q15 There are times when I feel very low -0.02474 -0.04879
Q16 I avoid responsibility if possible 0.00680 0.03665
Q17 I avoid mixing with people I don’t known well 0.00274 -0.00084
Q18 I feel as if I’m a burden to people -0.09989 -0.05433
Q19 I often forget what people have said to me 0.03700 -0.02075
Q20 I ﬁnd it difﬁcult to plan ahead -0.00941 -0.01288
Q21 I am easily irritated by other people -0.03853 -0.01329
Q22 I often feel too tired to do the thing I ought to do -0.05507 -0.01863
Q23 I have to force myself to do all the things that need doing 0.01142 0.00491
Q24 I often have to force myself to stay awake -0.01832 -0.01233
Q25 My memory lets me down -0.00874 -0.01183
Table 3 QoL-AGHDA scores in GHD patients without GH treatment and EQ-5D scores derived from those QoL-AGHDA scores
Sum score QoL-AGHDA QoL-AGHDA EQ-5Dscore
N Mean SD 20% 40% Median 60% 80% Mean Med SD
Belgium
Male 161 9.52 6.22 3.00 7.00 9.00 11.00 15.00 0.7827 0.8153 0.1510
Female 138 12.21 6.58 5.80 10.00 13.00 15.00 18.00 0.7129 0.7348 0.1666
The Netherlands
Male 116 8.40 6.67 2.00 5.80 7.00 10.00 15.00 0.8091 0.8312 0.1186
Female 118 11.28 6.75 4.00 10.00 11.00 14.00 18.00 0.7516 0.7707 0.1269
Mean age, 43.81; SD 15.27
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123of variables we did not include interaction in the analyses,
and therefore any interaction is ‘forced’ into the sign of the
variables. For this reason the positive signs found in this
study are not relevant in that respect, and the conceptual
interpretation of the sign should be made cautiously.
Implications
GHD burden in adults
We have shown that the burden of disease in adults with
GHD is considerable and comparable with other patients
whose burden is undisputed. This conﬁrms suggestions
made by others [1, 16, 28], but it is the ﬁrst time that such a
conclusion can be underpinned with a uni-dimensional
generic QoL questionnaire comparing QoL of GHD
patients with other patients. Former attempts made use of
multidimensional questionnaires and disease-speciﬁc
questionnaires, neither of which are not suitable for making
a decisive judgment [16, 28]. Using a multidimensional
questionnaire, it is not clear which of the dimensions are
the most important. Disease-speciﬁc questionnaires do not
allow for comparisons between patient groups, as impor-
tant other, i.e., non-disease-related (side) effects might be
overlooked. Therefore, disease-speciﬁc questionnaires
might not provide the full picture of the burden of disease.
But by using both a generic instrument and a validated
disease-speciﬁc instrument, we have provided new evi-
dence of a signiﬁcant burden in adults with GHD.
The evidence of a high burden of diseases found in this
study is obviously not a sufﬁcient condition either to
encourage treatment for GHD or to defend the reimburse-
ment of treatment. To justify treatment, it is necessary to
provide evidence that the burden of disease is reduced in a
clinically signiﬁcant way. To justify reimbursement of
treatment, it is further necessary that the treatment is rea-
sonably cost effective. Despite these limitations, burden of
disease plays an important role in reimbursement, because
burden of disease is an important factor in the interpreta-
tion of the cost effectiveness of treatment. If the burden of
disease is high, society is more inclined to be generous in
the interpretation of the cost effectiveness than when the
burden of disease is low [11, 12]. This study suggests that
the cost effectiveness of any GHD treatment should indeed
be interpreted generously and not restricted as if it was a
disease with a low burden.
Limitations of the study
Response rate
The response rate of the Dutch general population sample
was much higher (74%) than that of the Belgian sample
(15%). This was related to the way the samples were
recruited: Dutch respondents received a relatively high
compensation for their efforts, which contributed to a
higher response rate. In this respect it should be noted that
‘‘representativeness is more important than response rate in
survey research’’ [29]. It could be argued for instance that
the Dutch sample was less representative of the general
population as it consisted of ‘professional responders’,
while the Belgian sample was closer to the classical
objective of population research of achieving a ‘naı ¨ve
sample’. The line of reason is that we should deﬁne ‘‘what
the sample should be representative of’’. In our case we
wanted the samples to be representative of QoL, because
we wanted to have norm values for the QoL-AGHDA.
Therefore, factors that were associated with QoL were
more important than factors that had no such association.
As we know that age, gender and obviously ‘self-reported
health’ are associated with health-related QoL [30], we
weighted the samples for these factors using the ﬁgures of
the National Bureaus of Statistics. In this way the samples
used here represent the population of both countries with
respect to the most important determinants of health-rela-
ted QoL.
Criterion validity
The ICC between the estimated EQ-5Dindex on the basis of
the QoL-AGHDA and the ‘standard’ EQ-5Dindex was only
moderate (ICC = 0.4070), but comparable with the ICC
when the EQ-5D was compared with the SF-6D in patients
with ankylosing spondylitis (0.45) and in patients with
knee osteoarthritis (0.47) [31, 32]. The moderate ICC
suggests considerable differences at the individual level,
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123but small differences at the group level. Indeed we found
no statistically signiﬁcant difference between the estimated
EQ-5Dindex on the basis of the QoL-AGHDA and the
‘standard’ EQ-5Dindex. This means that our estimations of
the EQ-5Dindex on the basis of the QoL-AGHDA should
not be used at an individual patient level, but only when
sufﬁcient patient numbers are involved. When this meth-
odology was employed in GHD research, sufﬁcient patient
numbers were indeed used as the data came from the large
international KIMS database [9, 10].
Conclusions
In this article we have described Belgian and Dutch general
population reference values for the QoL-AGHDA and
provided a transformation function for the estimation of
EQ-5Dindex scores on the basis of QoL-AGHDA data. By
obtaining QoL-AGHDA reference values for the Nether-
lands and Belgium, the needs of patients with GHD can
now be understood more clearly. As we were able to link
the scores of the QoL-AGHDA to QALYs, we can now
evaluate the health outcomes of interventions better in
growth hormone deﬁciency. Based on these outcomes of
the QoL-AGHDA, we can also conﬁrm that the burden of
adults with GHD is considerable.
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